News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
264,946 Results
Type
Article (14122)
Company Profile (282)
Press Release (250542)
Section
Business (79466)
Career Advice (152)
Deals (13221)
Drug Delivery (35)
Drug Development (50412)
Employer Resources (31)
FDA (5706)
Job Trends (5125)
News (144312)
Policy (10025)
Tag
Academia (906)
Alliances (21613)
Alzheimer's disease (800)
Antibody-drug conjugate (ADC) (78)
Approvals (5710)
Artificial intelligence (98)
Bankruptcy (102)
Best Places to Work (4560)
Biotechnology (232)
Breast cancer (132)
Cancer (1148)
Cardiovascular disease (92)
Career advice (132)
CAR-T (99)
Cell therapy (286)
Clinical research (40614)
Collaboration (453)
Compensation (186)
COVID-19 (1028)
C-suite (122)
Cystic fibrosis (75)
Data (1183)
Diabetes (109)
Diagnostics (1282)
Earnings (29312)
Events (47791)
Executive appointments (368)
FDA (6230)
Funding (423)
Gene editing (79)
Gene therapy (207)
GLP-1 (341)
Government (1072)
Healthcare (6579)
Infectious disease (1081)
Inflammatory bowel disease (106)
IPO (7249)
Job creations (859)
Job search strategy (127)
Layoffs (197)
Legal (1384)
Lung cancer (164)
Manufacturing (105)
Medical device (2581)
Medtech (2582)
Mergers & acquisitions (6210)
Metabolic disorders (326)
Neuroscience (1125)
NextGen: Class of 2025 (2012)
Non-profit (852)
Northern California (1377)
Obesity (169)
Opinion (98)
Parkinson's disease (90)
Patents (92)
People (25389)
Phase I (14337)
Phase II (18898)
Phase III (11937)
Pipeline (548)
Postmarket research (852)
Preclinical (6006)
Radiopharmaceuticals (210)
Rare diseases (253)
Real estate (1414)
Regulatory (8464)
Research institute (935)
Series A (82)
Southern California (1231)
Startups (1969)
United States (10902)
Vaccines (192)
Weight loss (97)
Date
Today (6)
Last 7 days (472)
Last 30 days (1515)
Last 365 days (20323)
2025 (3122)
2024 (20552)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23356)
2019 (16223)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14350)
2014 (10393)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (148)
Asia (17124)
Australia (2896)
California (3149)
Canada (980)
China (283)
Colorado (119)
Connecticut (132)
Delaware (76)
Europe (36822)
Florida (366)
Georgia (93)
Illinois (195)
Indiana (76)
Maryland (409)
Massachusetts (2498)
Minnesota (123)
New Jersey (785)
New York (870)
North Carolina (485)
Northern California (1377)
Ohio (99)
Pennsylvania (593)
South America (207)
Southern California (1231)
Texas (351)
Washington State (296)
264,946 Results for "inhibikase therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Neurodegenerative disease
Inhibikase Scraps Parkinson’s Drug After Disappointing Mid-Stage Data
Inhibikase’s setback continues biopharma’s losing streak against Parkinson’s, marked by several clinical failures and abandoned assets in recent months.
January 30, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Inhibikase Announces Expansion of Senior Leadership Team
February 25, 2025
·
6 min read
Genetown
Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs
Inhibikase Therapeutics, Inc. today announced expansion of its therapeutic pipeline and multiple updates to its Research and Development programs.
June 5, 2024
·
6 min read
Press Releases
Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth
February 19, 2025
·
7 min read
Press Releases
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity
November 15, 2024
·
8 min read
Drug Development
Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s DiseaseCompany expects to report trial results in 4Q24
Inhibikase Therapeutics, Inc. today announced the company has completed enrollment in the Phase 2 ‘201’ trial evaluating the safety and tolerability of risvodetinib (“risvo”).
June 17, 2024
·
4 min read
Business
Inhibikase Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease, Parkinson’s-related disorders and other diseases of the Abelson Tyrosine Kinases, reported financial results for the first quarter ended March 31, 2024 and highlighted recent developments.
May 15, 2024
·
9 min read
Business
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
Inhibikase Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023 and highlighted recent developments.
March 27, 2024
·
11 min read
Genetown
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
Inhibikase Therapeutics, Inc. today issued a Letter to Shareholders.
December 19, 2023
·
6 min read
BioMidwest
Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
Inhibikase Therapeutics, Inc. announced that the Company has received final meeting minutes from its recent pre-IND meeting with the Division of Cardiology and Nephrology of the U.S. Food and Drug Administration for IkT-001Pro as a candidate treatment for Pulmonary Arterial Hypertension.
May 9, 2024
·
5 min read
1 of 26,495
Next
